Skip to content
Screener

10x Genomics, Inc. TXG License and royalty revenue — Revenue

Other product segments

Products and services revenue
$149.09M+2.7%
Services
$10.68M+26.0%
Spatial
$4.57M-47.8%
Single Cell
$3.09M-46.1%

Similar metrics at other companies

Microvision logo
MVISLicense And Royalty Revenue — Revenue
$18K-77.8%
Aquestive Therapeutics, Inc. logo
AQSTLicense and royalty revenue a — Revenue
$500K-40.4%
Aurinia Pharmaceuticals logo
AUPHLicense, collaboration and royalty revenue — Revenue
$3.81M+10.9%
Universal Display logo
OLEDRoyalty And License Fees — Revenue
$54.21M-26.3%
Under Armour logo
UAALicense revenues — Revenue
$24.81M+1.8%
Kopin logo
KOPNLicense And Other Revenues — Revenue
$64.93K-9.7%

Other financials

Income statement

See full
Revenue$151.0M-12.6%
Gross profit$112.5M-10.1%
Operating income-$19.6M-165%
Net income-$17.9M-152%
EPS (diluted)-$0.14-150%

Balance sheet

See full
Cash & equivalents$502.5M+26.4%
Total debt$78.8M-9.2%
Total equity$825.5M+6.8%
Total assets$1.0B+5.1%

Cash flow

See full
Operating cash flow$17.0M-4.1%
CapEx$1.6M+0.6%
Free cash flow$15.4M-4.6%

Valuation

See full
Market cap$5.79B+271%
Enterprise value$5.37B+330%
P/S9.4×+7.0×

Profitability

See full
Gross margin70%+0.5pp
Operating margin-14.3%-1.1pp
Net margin-12.2%-0.8pp
FCF margin19.7%+10.9pp

Returns & leverage

See full
Return on equity-9.4%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.7×-0.1×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054491
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Products and services revenue$149,094$145,157$298,990$282,980
License and royalty revenue1,94227,7512,88944,811
Revenue151,036172,908301,879327,791
Cost of products and services revenue38,53947,82483,20497,262
Gross profit112,497125,084218,675230,529
Operating expenses:
Research and development56,79161,224113,638125,469
Selling, general and administrative78,66174,434145,038164,162

Item 1. Financial Statements (Unaudited)

FAQ

What is 10x Genomics, Inc.'s license and royalty revenue — revenue?
10x Genomics, Inc. (TXG) reported license and royalty revenue — revenue of $1.94M in Q2 2026.
How has 10x Genomics, Inc.'s license and royalty revenue — revenue changed year-over-year?
10x Genomics, Inc.'s license and royalty revenue — revenue decreased by 93.0% year-over-year, from $27.75M to $1.94M.
What does license and royalty revenue — revenue mean?
This metric represents the revenue generated from granting third parties the right to use the company's intellectual property, patents, or proprietary technologies. It reflects the monetization of the company's research and development efforts through royalty payments or licensing fees rather than direct product sales. Growth in this segment indicates successful commercialization of the company's technology portfolio through strategic partnerships and intellectual property enforcement.

Ask your AI about 10x Genomics, Inc.'s license and royalty revenue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude